Wall Street brokerages expect Zafgen Inc (NASDAQ:ZFGN) to post ($0.37) earnings per share (EPS) for the current quarter, Zacks reports. Zero analysts have issued estimates for Zafgen’s earnings, with estimates ranging from ($0.41) to ($0.34). Zafgen reported earnings per share of ($0.57) in the same quarter last year, which suggests a positive year-over-year growth rate of 35.1%. The company is scheduled to issue its next earnings report on Tuesday, August 6th.
According to Zacks, analysts expect that Zafgen will report full year earnings of ($1.40) per share for the current financial year, with EPS estimates ranging from ($1.53) to ($1.30). For the next year, analysts anticipate that the firm will post earnings of ($1.37) per share, with EPS estimates ranging from ($1.76) to ($1.11). Zacks’ earnings per share calculations are an average based on a survey of research firms that that provide coverage for Zafgen.
Zafgen (NASDAQ:ZFGN) last posted its quarterly earnings data on Thursday, May 9th. The biopharmaceutical company reported ($0.35) EPS for the quarter, topping the Zacks’ consensus estimate of ($0.40) by $0.05.
A number of equities research analysts have recently issued reports on the company. JMP Securities boosted their target price on Zafgen from $8.00 to $17.00 and gave the stock a “hold” rating in a research report on Tuesday, March 12th. They noted that the move was a valuation call. ValuEngine lowered Zafgen from a “hold” rating to a “sell” rating in a research report on Wednesday, May 1st. Cowen reaffirmed a “hold” rating on shares of Zafgen in a research report on Thursday, January 17th. Zacks Investment Research raised Zafgen from a “sell” rating to a “hold” rating in a research report on Saturday, February 16th. Finally, Leerink Swann raised Zafgen from a “market perform” rating to an “outperform” rating and set a $4.52 target price on the stock in a research report on Thursday, February 7th. Two equities research analysts have rated the stock with a sell rating, four have assigned a hold rating and four have issued a buy rating to the company’s stock. The stock presently has a consensus rating of “Hold” and an average price target of $7.88.
ZFGN opened at $2.60 on Monday. Zafgen has a one year low of $2.33 and a one year high of $12.35. The company has a debt-to-equity ratio of 0.17, a quick ratio of 7.83 and a current ratio of 7.83. The firm has a market capitalization of $97.06 million, a PE ratio of -1.37 and a beta of -0.45.
Several institutional investors have recently made changes to their positions in the company. Candriam Luxembourg S.C.A. raised its position in Zafgen by 8.7% during the fourth quarter. Candriam Luxembourg S.C.A. now owns 539,000 shares of the biopharmaceutical company’s stock valued at $2,668,000 after buying an additional 43,000 shares during the period. Vanguard Group Inc raised its position in Zafgen by 14.1% during the third quarter. Vanguard Group Inc now owns 1,468,584 shares of the biopharmaceutical company’s stock valued at $17,168,000 after buying an additional 181,396 shares during the period. BlackRock Inc. raised its position in Zafgen by 47.6% during the third quarter. BlackRock Inc. now owns 2,121,820 shares of the biopharmaceutical company’s stock valued at $24,805,000 after buying an additional 683,888 shares during the period. Rhumbline Advisers raised its position in Zafgen by 66.7% during the fourth quarter. Rhumbline Advisers now owns 39,391 shares of the biopharmaceutical company’s stock valued at $195,000 after buying an additional 15,758 shares during the period. Finally, First Manhattan Co. acquired a new position in Zafgen during the fourth quarter valued at $27,000. 87.51% of the stock is currently owned by institutional investors.
Zafgen, Inc, a clinical-stage biopharmaceutical company, develops therapies for patients suffering from metabolic diseases comprising type 2 diabetes, Prader-Willi syndrome (PWS), and other metabolically related disorders. The company's lead product candidate is ZGN-1061, a fumagillin-class methionine aminopeptidase 2 (MetAP2) inhibitor administered by subcutaneous injection, which is in Phase 2 clinical trial and profiled for its utility in the treatment of type 2 diabetes and other related metabolic disorders.
Recommended Story: Growth and Income Funds
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Zafgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zafgen and related companies with MarketBeat.com's FREE daily email newsletter.